# SWOG S1505 (NCT02562716)

> S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

No report yet. It can be ordered.

- Drugs tested: mFOLFIRINOX; gemcitabine plus nab-paclitaxel
- Indication: resectable pancreatic adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02562716
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: SWOG Cancer Research Network
- Conditions: Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma
- Interventions: Fluorouracil; Gemcitabine Hydrochloride; Irinotecan Hydrochloride; Oxaliplatin; Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Pancreatectomy
- Enrollment: 147
- Primary outcome: Overall Survival (OS)

## Indexed commentary on SWOG S1505 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 28
- Podcasts: 5
- YouTube: 1

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=swog-s1505-nct02562716

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02562716", "email": "<work email>"}; the inbox owner confirms by the emailed link.